Research Shows New Treatment Effective for Vision Loss in Diabetics

Mon, 07 Jun 2010
A key new diabetes eye health study has the potential to alter the way in which vision loss is treated due to diabetic macular edema (DME).

DME is a highly serious complication related to diabetes.

12 months results from the Restore study highlight that 37 per cent of patients who were treated with just ranibizumab and 43 per cent of those treated with ranibizumab and laser therapy, experienced improvement in visual acuity by 10 letters or more on an eye chart.

This is in contrast to 16 per cent of patients treated with just laser, which is the present standard treatment for visual impairment as a result of DME.

These findings are a key step forward in ophthalmology, supporting evidence that ranibizumab is the first treatment in 25 years which has shown benefit over the present standard of care for visual impairment due to DME.

Ranibizumab is available and has been approved in 80 plus countries, for treating wet age-related macular degeneration (AMD).

It is not presently approved anywhere for the treatment of visual impairment as a result of DME.

Link to this page

Copy and Paste the following HTML into your page.